Article

CME-Supplement-December 2005

CME-Supplement-December 2005

Related Videos
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
Thomas Powles, MBBS, MRCP, MD, on efficacy of sasanlimab plus BCG in BCG-naïve NMIBC
1 expert in this video
Using Ultrasensitive PSA Assays in Routine Practice
1 expert in this video
Ultra-Low PSA Response as a Trial End Point or Clinical Decision Point
1 expert is featured in this series.
Outcomes in Black patients receiving darolutamide plus ADT for mHSPC
2 experts are featured in this series.
Key Benefits of PET in ccRCC Risk Stratification
4 experts in this video
Case 2: A 68-Year-Old Woman With Non–Muscle-Invasive Bladder Cancer
2 experts are featured in this series.
Early Detection of ccRCC
1 expert is featured in this series.
Comparing the safety profile of darolutamide with other androgen receptor inhibitors in Black patients
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Andrew Armstrong, MD, shares 5-year data on enzalutamide plus ADT in mHSPC
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Professor Dickon Hayne on bladder cancer data to watch for at ASCO 2025
Related Content
FDA approves darolutamide in metastatic castration-sensitive prostate cancer
June 3rd 2025

FDA approves darolutamide in metastatic castration-sensitive prostate cancer

Hannah Clarke
The approval is supported by data from the pivotal phase 3 ARANOTE trial.
Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP
June 2nd 2025

Pearls & Perspectives: Understanding and Improving Pelvic Health, with Diane Newman, DNP

Amy M. Pearlman, MD
Adding CAN-2409 to radiation significantly extends DFS in localized prostate cancer
June 3rd 2025

Adding CAN-2409 to radiation significantly extends DFS in localized prostate cancer

Hannah Clarke
"CAN-2409 immunotherapy could represent the first new therapy for men with localized prostate cancer in over 20 years," wrote the authors.
Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD
May 17th 2025

Pearls & Perspectives: From Guidelines to Practice—Navigating the TRT Treatment Spectrum, with Alex Tatem, MD

Amy M. Pearlman, MD Alex Tatem, MD
Explore the latest insights on testosterone therapy, its benefits, and practical applications from leading urologists in men's health.
Alicia Morgans, MD, MPH
June 3rd 2025

Phase 3 ARASTEP study to evaluate PSMA PET-CT–detected BCR in prostate cancer

Benjamin P. Saylor
“As of April 2025, 616 patients have been randomized,” said Alicia Morgans, MD, MPH.
Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC
June 2nd 2025

Adding lutetium (177Lu) vipivotide tetraxetan to SOC improves rPFS in mHSPC

Hannah Clarke
Data also showed a positive trend in overall survival.
© 2025 MJH Life Sciences

All rights reserved.